Treatment of chronic inflammatory diseases with biologic agents: Opportunities and risks for the elderly

Experimental Gerontology

Volumn 41, Issue 12, 2006, Pages 1250-1255

  Diaz Borjon, Alejandro ^a   Weyand, Cornelia M ^a   Goronzy, Jörg J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune rheumatic disease; B cells; Biologic agents; Elderly; T cells

Indexed keywords

ABATACEPT; ADALIMUMAB; ATLIZUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN; INFLIXIMAB; INFLUENZA VACCINE; INTERFERON; INTERLEUKIN 1BETA ANTIBODY; METHOTREXATE; PLACEBO; PNEUMOCOCCUS VACCINE; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIBAVIRIN; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AMYLOIDOSIS; ANKYLOSING SPONDYLITIS; ANTIGEN BINDING; CHRONIC INFLAMMATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CRYOGLOBULINEMIC VASCULITIS; DERMATOMYOSITIS; DIARRHEA; DRUG BINDING; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCARDITIS; GERIATRIC PATIENT; GIANT CELL ARTERITIS; GLOMERULONEPHRITIS; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; LABORATORY; LEUKOPENIA; LUNG ASPERGILLOSIS; MAINTENANCE THERAPY; MONONEUROPATHY MULTIPLEX; MONOTHERAPY; MYOPATHY; PNEUMONIA; POLYMYOSITIS; PREMEDICATION; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SHORT SURVEY; SIDE EFFECT; SOLID TUMOR; SPONDYLOARTHROPATHY; STOMATITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VASCULITIS; WEGENER GRANULOMATOSIS;

AGED; AMYLOIDOSIS; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; CRYOGLOBULINEMIA; HUMANS; MUSCULAR DISEASES; MUSCULOSKELETAL DISEASES; SPONDYLARTHROPATHIES; TEMPORAL ARTERITIS; VASCULAR DISEASES; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 33751515683     PISSN: 05315565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exger.2006.10.010     Document Type: Short Survey

References (28)

1. Basse G., Ribes D., Kamar N., Mehrenberger M., Esposito L., Guitard J., Lavayssiere L., Oksman F., Dur D., and Rostaing L. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 80 (2005) 1560-1564
2. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., and Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. Jama 295 (2006) 2275-2285
3. Breedveld F.C., Weisman M.H., Kavanaugh A.F., Cohen S.B., Pavelka K., van Vollenhoven R., Sharp J., Perez J.L., and Spencer-Green G.T. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54 (2006) 26-37
4. Cai F.Z., Ahern M., and Smith M. Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab. J. Rheumatol. 33 (2006) 1197-1198
5. Calabrese L.H., Zein N., and Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann. Rheum. Dis. 63 Suppl. 2 (2004) ii18-ii24
6. Calabrese L.H., Zein N.N., and Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann. Rheum. Dis. 65 (2006) 983-989
7. Cancro M.P. B cells and aging: gauging the interplay of generative, selective, and homeostatic events. Immunol. Rev. 205 (2005) 48-59
8. Davis Jr. J.C., Van Der Heijde D., Braun J., Dougados M., Cush J., Clegg D.O., Kivitz A., Fleischmann R., Inman R., and Tsuji W. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 48 (2003) 3230-3236
9. Efthimiou P., Schwartzman S., and Kagen L.J. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann. Rheum. Dis. 65 (2006) 1233-1236
10. Emery P., Fleischmann R., Filipowicz-Sosnowska A., Schechtman J., Szczepanski L., Kavanaugh A., Racewicz A.J., van Vollenhoven R.F., Li N.F., Agarwal S., Hessey E.W., and Shaw T.M. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54 (2006) 1390-1400
11. Fernandez-Nebro A., Tomero E., Ortiz-Santamaria V., Castro M.C., Olive A., de Haro M., Portales R.G., Gonzalez-Mari M.V., Laffon A., and Garcia-Vicuna R. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am. J. Med. 118 (2005) 552-556
12. Goodwin K., Viboud C., and Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24 (2006) 1159-1169
13. Goronzy J.J., and Weyand C.M. T cell development and receptor diversity during aging. Curr. Opin. Immunol. 17 (2005) 68-475
14. Grubeck-Loebenstein B., and Wick G. The aging of the immune system. Adv. Immunol. 80 (2002) 243-284
15. Hoffman, G.S., Cid, M.C., Rendt, K.E., Merkel, P.A., Weyand, C.M., Stone, J.H., Salvarani, C., Xu, W., Visvanathan, S., Rahman, M.U., in press. Prednisone and infliximab for giant cell arteritis: a randomized, double-blind, placebo-controlled, multicenter study of efficacy and safety. Ann. Intern. Med.
16. Kapetanovic M.C., Saxne T., Sjoholm A., Truedsson L., Jonsson G., and Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 45 (2006) 106-111
17. Kremer J.M., Genant H.K., Moreland L.W., Russell A.S., Emery P., Abud-Mendoza C., Szechinski J., Li T., Ge Z., Becker J.C., and Westhovens R. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 144 (2006) 865-876
18. Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., Smolen J.S., Weisman M., Emery P., Feldmann M., Harriman G.R., and Maini R.N. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N. Engl. J. Med. 343 (2000) 1594-1602
19. Nishimoto N. Interleukin-6 in rheumatoid arthritis. Curr. Opin. Rheumatol. 18 (2006) 277-281
20. Quartuccio L., Soardo G., Romano G., Zaja F., Scott C.A., De Marchi G., Fabris M., Ferraccioli G., and De Vita S. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford) 45 (2006) 842-846
21. Salvarani C., Manzini C., Paolazzi G., Trotta A., Manganelli P., Cimmino M., Gerli R., Catanoso M., Boiardi L., Germanò G., Macchioni P., and Cantini F. Infliximab in the treatment of polymyalgia rheumatica: a double blind, randomized, placebo controlled study. Arthritis Rheum. 52 (2005) s676-s677
22. Stone J.H., Holbrook J.T., Marriott M.A., Tibbs A.K., Sejismundo L.P., Min Y.I., Specks U., Merkel P.A., Spiera R., Davis J.C., St Clair E.W., McCune W.J., Ytterberg S.R., Allen N.B., and Hoffman G.S. Solid malignancies among patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum. 54 (2006) 1608-1618
23. van der Heijde D., Klareskog L., Rodriguez-Valverde V., Codreanu C., Bolosiu H., Melo-Gomes J., Tornero-Molina J., Wajdula J., Pedersen R., and Fatenejad S. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 54 (2006) 1063-1074
24. van der Kolk L.E., Baars J.W., Prins M.H., and van Oers M.H. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 100 (2002) 2257-2259
25. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group, 2005. Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med. (352), 351-361.
26. Weyand C.M., Fulbright J.W., and Goronzy J.J. Immunosenescence, autoimmunity, and rheumatoid arthritis. Exp. Gerontol. 38 (2003) 833-841
27. Weyand C.M., and Goronzy J.J. Medium- and large-vessel vasculitis. N. Engl. J. Med. 349 (2003) 160-169
28. Zaja F., De Vita S., Mazzaro C., Sacco S., Damiani D., De Marchi G., Michelutti A., Baccarani M., Fanin R., and Ferraccioli G. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101 (2003) 3827-3834